Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the best tagging SNPs from our previous PTC study and additionally included SNPs in or near FOXE1 and NKX2-1 genes, known susceptibility loci for thyroid cancer.
|
27207655 |
2016 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Twenty-four (27%) of 89 patients were diagnosed with thyroid cancer (50% papillary thyroid carcinoma [PTC], 50% follicular variant of papillary thyroid carcinoma [FVPTC]).
|
25627462 |
2015 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of 265 TC, 34 (12.8%) harbored TERT promoter mutations, including 10/153 (6.5%) conventional papillary TC (CPTC), 8/57 (14.0%) follicular variant PTC, 9/30 (30%) tall cell variant PTC, 1/3 (30%) Hurthle cell thyroid cancer (HTC), 1/5 (20%) follicular TC, and 5/13 (38.5%) poorly differentiated TC.
|
26354077 |
2015 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, expression of Sin1 and activation of AKT kinase were analyzed in fresh-frozen tissue samples (normal/tumor), primary cell cultures (papillary thyroid carcinoma [PTC]), and an established thyroid cancer cell line (medullary thyroid carcinoma) by Western blotting.
|
25456951 |
2014 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.
|
24811481 |
2014 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC is a characteristic genetic alteration frequently found in radiation-induced thyroid cancer in human populations.
|
22136268 |
2011 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several types of rearrangement known to occur in thyroid cancer, including RET/PTC, NTRK1 and BRAF/AKAP9, are more common in radiation-associated thyroid tumors and RET/PTC can be induced experimentally by exposing human thyroid cells to ionizing radiation.
|
19766698 |
2010 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even though RET/PTC is a specific genetic event in the carcinomas, our results suggested the possibility of RET/PTC as "passenger" abnormalities rather than "driver" oncogenic mutation during thyroid cancer progression, warranting further studies on mechanisms and implication of RET gene instability.
|
19495791 |
2009 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In fact, it has been demonstrated that: a) RET/PTC is an early event in the process of thyroid carcinogenesis and has a critical role in the generation of the papillary carcinoma; b) RET/PTC activation is essentially restricted to the papillary histotype and to the Hürthle thyroid tumors; c) its incidence increases after exposure to radiations.
|
17891236 |
2007 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic proteins such as Ret/PTC, Ras and BRAF can induce NF-kappaB activation making it an important change in thyroid cancer.
|
17891249 |
2007 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we use an 18 Mb region on 10q11.2-21 containing the RET gene and its recombination partners, the H4 and NCOA4 (ELE1) genes, as a model chromosomal region frequently involved in RET/PTC rearrangements in thyroid cancer.
|
16331264 |
2006 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the methylation pattern of 17 gene promoters in nine thyroid cancer cell lines and in 38 primary thyroid carcinomas (13 papillary thyroid carcinoma [PTC], 10 follicular thyroid carcinoma [FTC], 9 undifferentiated thyroid carcinoma [UTC], 6 medullary thyroid carcinoma [MTC]), 12 goiters, and 10 follicular adenomas (FA) by methylation- specific polymerase chain reaction (PCR).
|
16889486 |
2006 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical technique is proved to be a useful tool to detect RFT/PTC activation in thyroid tumors.
|
15368067 |
2005 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors investigated the prevalence of RET/PTC in a large number of thyroid tumors from Japanese patients.
|
16015630 |
2005 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood.
|
15126554 |
2004 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
RET/PTC rearrangement in thyroid tumors.
|
12114746 |
2002 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have demonstrated that there is a high preponderance of ras and ret/PTC oncogenes in the evolution of thyroid cancer.
|
12240753 |
2002 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relatively low prevalence of RET activation in PDCs argues against a major role for RET/PTC in the progression from well to poorly differentiated thyroid tumor phenotypes.
|
11788678 |
2002 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer.
|
11344225 |
2001 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We designed the present study to evaluate in a single laboratory, using the same methodologies, the pattern of RET/PTC activation in thyroid tumors from different groups of patients (exposed or not exposed to radiation, children or adults, with benign or malignant tumors) in relationship to the above mentioned variables.
|
11443191 |
2001 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Present data suggest that: (1) the incidence of FAP-associated thyroid cancer probably has been underestimated in the past; (2) intensive screening could detect a larger than expected number of thyroid carcinomas; (3) systematic screening is recommended in patients with ocular patches and genetic mutation in exon 15; (4) Hashimoto-like findings do not exclude carcinoma but are a frequent accompanying finding; (5) despite frequent multicentricity and early lymph node involvement, FAP-associated thyroid tumors seem to have an excellent prognosis, in particular those showing ret-PTC activation.
|
9841749 |
1998 |